K-pio-GM tablet uses and side effects
Reading Document
Medical Text Search
pioglitazone metformin combination tablet uses indications
Medical Text Search
pioglitazone metformin side effects adverse effects contraindications
GradeResponse
GradeResponse
K-pio-GM Tablet
K-pio-GM is a fixed-dose combination tablet containing Pioglitazone + Metformin, used in the management of Type 2 Diabetes Mellitus (T2DM). Common brand variants include different strengths (e.g., Pioglitazone 15 mg + Metformin 500/850 mg).
Mechanism of Action
| Component | Class | Mechanism |
|---|---|---|
| Pioglitazone | Thiazolidinedione (TZD) | PPAR-γ agonist → improves insulin sensitivity in muscle, fat, and liver |
| Metformin | Biguanide | Reduces hepatic glucose production; improves peripheral insulin sensitivity |
The combination provides complementary dual action — addressing both insulin resistance and hepatic glucose overproduction.
Uses / Indications
- Type 2 Diabetes Mellitus — as an adjunct to diet and exercise when blood glucose is inadequately controlled on metformin or pioglitazone alone
- Particularly useful in patients with significant insulin resistance
- May be considered in patients with metabolic syndrome or non-alcoholic fatty liver disease (NAFLD)
- The PROACTIVE trial showed pioglitazone significantly reduced all-cause mortality, non-fatal MI, and stroke in high-risk T2DM patients (HR 0.84, 95% CI 0.72–0.98)
Side Effects
Pioglitazone-related
| Side Effect | Details |
|---|---|
| Weight gain | Due to fluid retention and adipogenesis |
| Fluid retention / edema | Can worsen or precipitate heart failure |
| Bladder cancer risk | Increased with prolonged use (>1 year); monitor accordingly |
| Bone fractures | Increased risk of non-axial fractures, particularly in women |
| Hepatotoxicity | Rare; monitor liver function |
| Macular edema | Rare but reported |
Metformin-related
| Side Effect | Details |
|---|---|
| GI disturbances | Nausea, vomiting, diarrhea, abdominal discomfort (most common, often transient) |
| Lactic acidosis | Rare but serious; risk increases with renal impairment, contrast agents, surgery |
| Vitamin B12 deficiency | With long-term use; monitor periodically |
| Metallic taste | Common, especially at initiation |
Contraindications
- Heart failure (NYHA Class III/IV) — pioglitazone is contraindicated
- Renal impairment (eGFR <30 mL/min) — metformin is contraindicated
- Active bladder cancer or history of bladder cancer
- Hepatic impairment
- Pregnancy and breastfeeding
- Before iodinated contrast procedures (hold metformin)
Key Precautions
- Monitor renal function, liver enzymes, and CBC periodically
- Use with caution in elderly patients (lactic acidosis risk with metformin)
- Avoid alcohol (increases lactic acidosis risk)
- Reassess bladder cancer risk in patients on long-term pioglitazone
- Watch for signs of heart failure (dyspnea, edema, rapid weight gain)
Clinical note: K-pio-GM combines two insulin-sensitizing agents with complementary mechanisms. It is well-tolerated in most patients but requires careful monitoring for fluid retention, renal function, and bladder cancer risk with prolonged use. Always individualize therapy based on patient comorbidities.
This is a shared conversation. Sign in to Orris to start your own chat.